Menopause and hair thinning: the London 2026 clinical guide

For the average London woman entering perimenopause, hair change is one of the most distressing symptoms — and one of the most under-treated. Menopause hubs on the NHS focus on flushes, mood and osteoporosis; hair thinning tends to be filed under 'ageing' and dismissed. It shouldn't be. Menopausal hair thinning has clear hormonal drivers, well-characterised patterns, and evidence-based treatments that work — provided they are started early.

What is actually happening

Oestrogen prolongs the growth (anagen) phase of the hair cycle and protects follicles from androgen influence. As oestrogen falls in perimenopause and menopause, two things happen:

• Anagen shortens: hairs spend less time growing, more in rest and shedding. Density falls.
• Relative androgen dominance rises: even without changes in absolute androgen levels, the ratio shifts. Follicles genetically susceptible to androgens begin miniaturising — producing shorter, thinner, weaker hairs.
• This is female androgenetic alopecia expressing itself under changed hormonal conditions.

The two dominant patterns

Menopausal hair change in London clinics falls broadly into two presentations:

• Diffuse pattern (Ludwig I–II): thinning centred on the central parting, widening over months. Hairline preserved. This is the most common presentation and responds well to medical therapy.
• Frontal fibrosing alopecia (FFA): hairline recession, often with loss of eyebrows and occasional facial papules. This is a scarring alopecia — irreversible if untreated. Needs dermatology referral. Incidence has risen sharply in the last decade for reasons still being investigated.

HRT and hair — the honest picture

HRT can significantly slow, and sometimes reverse, menopausal hair thinning — particularly when started in the perimenopausal window. Its effect on hair depends on:

• The oestrogen dose and route (transdermal is generally preferred over oral for hair — less SHBG effect).
• The progestogen type — micronised progesterone is typically hair-friendlier than older synthetic progestins.
• Whether testosterone is added — small doses of transdermal testosterone (Testogel or AndroFeme) are increasingly used in London for libido and energy, but the hair effect can go either way. Discuss with a menopause specialist.
• The presence or absence of underlying androgenetic pattern — HRT slows the driver but doesn't reverse fully-established pattern loss.

Topical minoxidil — the foundation

Topical minoxidil 5% (foam or liquid) is the strongest evidence-based topical intervention for female pattern hair loss and remains the London first-line. Applied once or twice daily to the affected area, it prolongs anagen and enlarges follicles.

• Foam is generally preferred — less residue, better tolerated on colour-treated hair.
• First visible change at month 4–6. Peak at month 12.
• A temporary shed at week 2–8 is normal — do not stop.
• Reversible: stopping regrows lost effect over 6–12 months. Long-term commitment required.

Low-dose oral minoxidil — the London shift

Over the last 24 months, low-dose oral minoxidil (0.625–2.5mg once daily) has quietly become the most common systemic intervention for menopausal hair thinning in London specialist clinics. Reasons: adherence, consistency of effect, absence of scalp irritation.

• Start dose typically 0.625mg (quarter of a 2.5mg tablet).
• Titrate up to 1.25–2.5mg over 4–8 weeks based on tolerance.
• Main side effect: mild facial hair growth in ~15–30%. Usually manageable with laser or waxing.
• Requires blood pressure check and cardiac history review before prescribing.

Spironolactone — the anti-androgen

Spironolactone (25–200mg/day) is a potassium-sparing diuretic with anti-androgen effect. It has decades of use for female androgenetic alopecia and is increasingly first-line alongside minoxidil in London.

• Typical starting dose: 50mg daily, titrated up to 100–200mg based on tolerance.
• Side effects: menstrual irregularity (rare post-menopause), breast tenderness, transient dizziness.
• Monitor potassium at 4–6 weeks after starting.
• Contraindicated with strong potassium-raising medications (ACE inhibitors) — GP or specialist should coordinate.

The workup — what should be checked

Any London consultation for menopausal hair thinning should include the following baseline:

• Ferritin — target >70 ng/mL, not just 'not anaemic'.
• TSH, free T4 — thyroid dysfunction is a common overlap.
• Vitamin D — target >75 nmol/L.
• B12, folate — check and correct if borderline.
• Free androgen index or testosterone + SHBG — establishes androgen state.
• Trichoscopy — differentiates pattern loss from telogen effluvium and scarring alopecias.

Frontal fibrosing alopecia — the escalation flag

FFA presents as a slowly receding, symmetrical hairline in post-menopausal women, often with loss of eyebrows and sometimes small skin-coloured facial papules. It is not just recession — it is scarring alopecia, meaning the follicles are being destroyed and cannot be recovered once lost.

• Immediate dermatology referral is warranted.
• Treatment: topical or intralesional corticosteroids, hydroxychloroquine, sometimes low-dose oral minoxidil and finasteride/dutasteride.
• Ceasing progression is realistic; regrowth of already-lost hair is not.
• Early recognition is the entire game.

Scalp health in this population

Menopause changes scalp physiology beyond just hair follicles. Sebum production shifts, the skin barrier weakens, and sensitivity to previously tolerated products increases. A gentle scalp routine — sulphate-free shampoo, weekly gentle exfoliation, avoidance of aggressive clarifying products, and a monthly salon-based scalp facial — makes a meaningful difference alongside medical therapy.

The London protocol — a realistic 12-month plan

• Month 0: full workup — bloods, trichoscopy, menopause specialist review, HRT started or optimised if appropriate.
• Month 0–1: topical minoxidil 5% foam once daily. Consider spironolactone 50mg daily.
• Month 3: reassess. Increase minoxidil to twice daily if tolerated. Titrate spironolactone to 100mg.
• Month 6: photographic review. Add or switch to low-dose oral minoxidil if adherence is an issue.
• Month 9–12: full assessment. If insufficient response, consider adding PRP course, microneedling, or specialist escalation.

The bottom line

Menopausal hair thinning is one of the most treatable presentations in modern trichology — provided it is addressed early, with the right hormonal and topical/systemic combination, and provided FFA is not missed. Do not accept 'it's just the menopause' as a plan. Get the workup. Start therapy. Give it 12 months.